FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207079654> ?p ?o ?g. }

• W3207079654 abstract "<h3>Introduction/Background*</h3> Clinical trials consistently demonstrate the detrimental impact of progressive disease (PD) on patients’ health-related quality of life (HRQoL). Progression-free survival (PFS) is an established regulatory endpoint. However, PFS is often excluded as an efficacy endpoint on the basis that — PFS is not patient relevant — in early benefit assessment by select EU health technology agencies. The PRIMA/ENGOT-OV26/GOG-3012 (NCT02655016) Phase 3 trial showed niraparib significantly prolongs median PFS vs placebo in patients with AOC responsive to 1L platinum (Pt)-based chemotherapy, (CT), regardless of biomarker status. This post-hoc analysis of PRIMA is the first study to examine the relationship between HRQoL and PD in a broad frontline AOC maintenance treatment setting. <h3>Methodology</h3> In PRIMA, patients with AOC responsive to 1L Pt CT were randomised 2:1 to once-daily, maintenance niraparib or placebo. Impact of PD on patient HRQoL, irrespective of treatment, was evaluated within the pooled ITT population by comparing HRQoL at the last on-treatment (pre-progression) visit with HRQoL at end of treatment (EOT), +4 weeks, +8w, +12w, and +24w. Assessments included FOSI, EORTC QLQ-C30, EQ-5D-VAS, and EORTC QLQ-OV28 abdominal/GI symptom scale. ANCOVA was applied with treatment as a fixed effect and HRQoL at last on-treatment visit as a continuous covariate. Mixed models for repeated measurements (MMRM) evaluated cumulative HRQoL changes. <h3>Result(s)*</h3> Significant reductions in HRQoL from pre- to post-progression were observed across all measures. Compared with pre-progression, FOSI scores (Least-squares mean [95% CI]) were lower at EOT+4w (-2.2 [-2.8, -1.6]) and EOT+24w (-1.7 [-2.3, -1.1]); each p<0.0001. Similarly, at these timepoints EORTC-QLQ-C30 scores were lower by -10.2 (-12.4, -8.0) and -10.7 (13.2, -8.2) points, respectively, and EQ-5D-VAS by -8.2 (-10.4, -6.0) and -6.2 (-8.2, -4.2) points, respectively; each p<0.0001. EORTC QLQ-OV28 scores were significantly worse at EOT+4w (6.6 [4.3, 8.9]) and EOT+24w (5.0 [2.8, 7.2]); each p<0.0001. Similar changes were seen on MMRM analysis. <h3>Conclusion*</h3> These findings demonstrate HRQoL is negatively impacted by PD in AOC. Preservation of HRQoL, an important therapy goal in the maintenance setting particularly for asymptomatic patients, can be achieved with PFS prolongation. PFS is of significant relevance and clinically important for AOC patients." @default.
• W3207079654 created "2021-10-25" @default.
• W3207079654 creator A5000448920 @default.
• W3207079654 creator A5002158178 @default.
• W3207079654 creator A5007158755 @default.
• W3207079654 creator A5007605375 @default.
• W3207079654 creator A5007606531 @default.
• W3207079654 creator A5008545738 @default.
• W3207079654 creator A5010308279 @default.
• W3207079654 creator A5020292607 @default.
• W3207079654 creator A5021359849 @default.
• W3207079654 creator A5028895212 @default.
• W3207079654 creator A5034544552 @default.
• W3207079654 creator A5039578268 @default.
• W3207079654 creator A5040462549 @default.
• W3207079654 creator A5045689760 @default.
• W3207079654 creator A5057030543 @default.
• W3207079654 creator A5061939825 @default.
• W3207079654 creator A5066283666 @default.
• W3207079654 creator A5070740646 @default.
• W3207079654 creator A5081892498 @default.
• W3207079654 creator A5089418421 @default.
• W3207079654 date "2021-10-01" @default.
• W3207079654 modified "2023-10-17" @default.
• W3207079654 title "961 Impact of disease progression on health-related quality of life of advanced ovarian cancer (AOC) patients – pooled analysis from the PRIMA trial" @default.
• W3207079654 doi "https://doi.org/10.1136/ijgc-2021-esgo.494" @default.
• W3207079654 hasPublicationYear "2021" @default.
• W3207079654 type Work @default.
• W3207079654 sameAs 3207079654 @default.
• W3207079654 citedByCount "1" @default.
• W3207079654 countsByYear W32070796542022 @default.
• W3207079654 crossrefType "proceedings-article" @default.
• W3207079654 hasAuthorship W3207079654A5000448920 @default.
• W3207079654 hasAuthorship W3207079654A5002158178 @default.
• W3207079654 hasAuthorship W3207079654A5007158755 @default.
• W3207079654 hasAuthorship W3207079654A5007605375 @default.
• W3207079654 hasAuthorship W3207079654A5007606531 @default.
• W3207079654 hasAuthorship W3207079654A5008545738 @default.
• W3207079654 hasAuthorship W3207079654A5010308279 @default.
• W3207079654 hasAuthorship W3207079654A5020292607 @default.
• W3207079654 hasAuthorship W3207079654A5021359849 @default.
• W3207079654 hasAuthorship W3207079654A5028895212 @default.
• W3207079654 hasAuthorship W3207079654A5034544552 @default.
• W3207079654 hasAuthorship W3207079654A5039578268 @default.
• W3207079654 hasAuthorship W3207079654A5040462549 @default.
• W3207079654 hasAuthorship W3207079654A5045689760 @default.
• W3207079654 hasAuthorship W3207079654A5057030543 @default.
• W3207079654 hasAuthorship W3207079654A5061939825 @default.
• W3207079654 hasAuthorship W3207079654A5066283666 @default.
• W3207079654 hasAuthorship W3207079654A5070740646 @default.
• W3207079654 hasAuthorship W3207079654A5081892498 @default.
• W3207079654 hasAuthorship W3207079654A5089418421 @default.
• W3207079654 hasBestOaLocation W32070796541 @default.
• W3207079654 hasConcept C102959455 @default.
• W3207079654 hasConcept C105795698 @default.
• W3207079654 hasConcept C121608353 @default.
• W3207079654 hasConcept C126322002 @default.
• W3207079654 hasConcept C142724271 @default.
• W3207079654 hasConcept C143998085 @default.
• W3207079654 hasConcept C159110408 @default.
• W3207079654 hasConcept C1862650 @default.
• W3207079654 hasConcept C203092338 @default.
• W3207079654 hasConcept C204787440 @default.
• W3207079654 hasConcept C27081682 @default.
• W3207079654 hasConcept C2776694085 @default.
• W3207079654 hasConcept C2779951463 @default.
• W3207079654 hasConcept C2780427987 @default.
• W3207079654 hasConcept C2780739268 @default.
• W3207079654 hasConcept C2908647359 @default.
• W3207079654 hasConcept C33923547 @default.
• W3207079654 hasConcept C535046627 @default.
• W3207079654 hasConcept C67761136 @default.
• W3207079654 hasConcept C71924100 @default.
• W3207079654 hasConcept C99454951 @default.
• W3207079654 hasConceptScore W3207079654C102959455 @default.
• W3207079654 hasConceptScore W3207079654C105795698 @default.
• W3207079654 hasConceptScore W3207079654C121608353 @default.
• W3207079654 hasConceptScore W3207079654C126322002 @default.
• W3207079654 hasConceptScore W3207079654C142724271 @default.
• W3207079654 hasConceptScore W3207079654C143998085 @default.
• W3207079654 hasConceptScore W3207079654C159110408 @default.
• W3207079654 hasConceptScore W3207079654C1862650 @default.
• W3207079654 hasConceptScore W3207079654C203092338 @default.
• W3207079654 hasConceptScore W3207079654C204787440 @default.
• W3207079654 hasConceptScore W3207079654C27081682 @default.
• W3207079654 hasConceptScore W3207079654C2776694085 @default.
• W3207079654 hasConceptScore W3207079654C2779951463 @default.
• W3207079654 hasConceptScore W3207079654C2780427987 @default.
• W3207079654 hasConceptScore W3207079654C2780739268 @default.
• W3207079654 hasConceptScore W3207079654C2908647359 @default.
• W3207079654 hasConceptScore W3207079654C33923547 @default.
• W3207079654 hasConceptScore W3207079654C535046627 @default.
• W3207079654 hasConceptScore W3207079654C67761136 @default.
• W3207079654 hasConceptScore W3207079654C71924100 @default.
• W3207079654 hasConceptScore W3207079654C99454951 @default.
• W3207079654 hasLocation W32070796541 @default.
• W3207079654 hasOpenAccess W3207079654 @default.
• W3207079654 hasPrimaryLocation W32070796541 @default.
• W3207079654 hasRelatedWork W1608269846 @default.
• W3207079654 hasRelatedWork W2512949579 @default.

• next